Specifically, the absence of SOCS2 did not affect the disease latency and the histological presentation of CML in mice transplanted with BCR-ABL transduced bone marrow (BM) cells [107]. This evidence concerns the gene SOCS2 and chronic myelogenous leukemia, BCR-ABL1 positive.